Milestone payments from collaborations contributed to a 27% rise in revenue to €12.8 million at Ablynx NV in the first half of 2011. Meanwhile, the company’s technology achieved its first clinical proof-of-concept in a trial for rheumatoid arthritis (RA) during the period.
